The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
Supplementary Materials and Methods

Tissue specimens, cell lines and reagents
The collection of tumor and adjacent normal liver tissues from HCC patients were approved by our Institutional Review Board (IRB) and all tissues studied were provided by the Tissue Repository of the National Cancer Centre Singapore (NCCS) and Cancer Center, Sun Yat-Sen University. Written informed consent was obtained from all participating patients and all clinical and histopathological data provided to the researchers were rendered anonymous. Liver cancer cells were cultured in Dulbecco's modified Eagle's medium (HepG2, HuH7, PLC/PRF/5, HCCLM3, HLE, Mahlavu, SNU-449, SK-HEP-1), with 10% FBS and 100 units/mL of penicillin and 100 µg/mL of streptomycin (Invitrogen, Carlsbad, CA). All cell lines were maintained at 37°C in the presence of 5% CO 2 . Sorafenib was from Bayer HealthCare Pharmaceuticals, Inc. and YM155 was synthesised by MedChemexpress Co. Ltd and Biochempartner Co. Ltd (Shanghai, China).
RNA extraction, microarray and Real-time quantitative RT-PCR (qRT-PCR) analysis
Total RNA from the tissue samples or cell lines was extracted using TRIzol reagent (Invitrogen). The quality and quantity of isolated total RNA were assessed using the Agilent 2100 Bioanalyzer and NanoDrop ND-1000 Spectrophotometer (Agilent, Santa Clara, CA, USA). Microarray analysis was performed as described [22] using the GeneChip® Human Gene ST Arrays (Affymetrix, USA) according to the manufacturers' instructions. Post hybridization washes were performed on an Affymetrix GeneChip Fluidics Station 450. Arrays were scanned on an Affymetrix GeneChip Scanner 3000.
Scanned arrays were normalized using GCRMA in Partek software (Partek Incorporated.
St. Louis, MO). Array quality control was performed using Affymetrix® Expression
Console™. Signal intensities were transformed to log2 base and imported to Partek with hypoxanthine phosphoribosyltransferase 1 (HPRT1) as an internal control as described previously, and fold changes were calculated via relative quantification (2 -ΔCt ).
Western blotting
Protein was isolated using RIPA. Antibodies used for western blotting were: rabbit antisurvivin (#2808) or phospho-Survivin (Thr34) (D2E11) Rabbit mAb (#8888) (Cell Signaling, MA); mouse anti-PARP-1 and Caspase-3 (Santa Cruz, CA) and goat GAPDH (GenScript, NJ).
Immunohistochemistry (IHC)
The IHC was performed as described previously. Primary antibodies used included the rabbit anti-survivin (#2808) (Cell Signaling, MA) (1:100), or an isotype-matched IgG as a negative control. Intensity of staining was evaluated based on a scale of 0 to 4 according to the percentage of positive tumours (0, negative control; +, 0%-10%; ++, 10%-25%; +++, 25%-50% and ++++, >50%).
Immunofluorescence analysis
HCC cells were seeded in the BD Falcon™ 8-well CultureSlide and treated with YM155 (10 ng/ml) for 24 hours. The treated cells were fixed and incubated with primary antibodies against p-H2AX and then incubated with Alexa Fluor® 488 goat anti-rabbit IgG (Invitrogen). Slides were counterstained with Hoechst 33342 and imaged using a confocal laser-scanning microscope (Carl Zeiss).
Animal studies
All experiments were approved by the Institutional Animal Care and Use Committee of SingHealth. All mice studies were done in the Animal Unit with AAALAC accreditation in National Cancer Center Singapore. Mahlavu-and HuH7-luciferase expressing cells were firstly subcutaneously injected into 5-to 6-week-old athymic mice (2 mice per group, BioLASCO Taiwan Co, Ltd) to generate tumor. The tumor-bearing mice were anesthetized with Hypnorm/Midazolam and a small piece of tumor was harvested and orthotopically transplanted to the liver of the recipient mice as described previously [18] to establish the orthotopic mouse liver tumor xenograft model. One week after implantation, the mice were imaged and grouped. Mice with similar signals were grouped (10 mice/group) and treated either with YM155, sorafenib or saline for 7 weeks.
Sorafenib was administered at the effective dose of 30 mg/kg/dose, p.o. Mice were treated with YM155 for 7 days with a continuous intraperitoneal injection of 10 mg/kg, followed by a 7-day rest period. Each cycle was repeated every 14 days for a total of 4 cycles of treatment. Tumor growth was monitored every week by bioluminescence imaging using the Xenogen IVIS Lumina system (Xenogen Corporation, Hopkinton, MA). 
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